| 2026-08-13 | 8-K | Form 8-K, Item 1.01 |
| 2026-08-12 | Press release | AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants |
| 2026-08-11 | Press release | AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants |
| 2026-08-10 | Deck | Investor presentation · Q3 2026 · Aug 2026 |
| 2026-08-10 | Press release | AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in |
| 2026-08-10 | 8-K | Form 8-K, Item 7.01 |
| 2026-08-07 | Press release | AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due |
| 2026-08-07 | 8-K | Form 8-K, Item 8.01 |
| 2026-08-05 | Press release | AbCellera Reports Q2 2026 Business Results |
| 2026-08-05 | Deck | Q2 2026 Earnings Results and Business Update |
| 2026-08-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-05 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| Transcript | Q2 FY26 earnings call transcript |
| 2026-07-29 | Press release | AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Othe |
| 2026-07-29 | 8-K | Form 8-K, Item 8.01 |
| 2026-07-07 | Press release | AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026 |
| 2026-07-07 | Press release | AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026 |
| 2026-07-06 | Press release | Download , AbCellera Appoints Dr. Lynn Seely to its Board of Directors |
| 2026-07-06 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-17 | Press release | Download , Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multisp |
| 2026-06-17 | 8-K | Form 8-K, Item 8.01 |
| 2026-06-12 | 8-K | Form 8-K, Item 5.07 |
| 2026-06-05 | Press release | Download , AbCellera Appoints Dr. Victor Sandor to its Board of Directors |
| 2026-06-05 | 8-K | Form 8-K, Item 5.02 |
| 2026-05-12 | Transcript | Q1 FY26 earnings call transcript |
| 2026-05-11 | Deck | Q1 2026 Earnings Results and Business Update |
| 2026-05-11 | Document | Call Summary · Q1 2026 |
| 2026-05-11 | Press release | Download , AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635, Ma |
| 2026-05-11 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-11 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-07 | Press release | Download , AbCellera to Present at Upcoming Investor Conferences in May and June 2026 |
| 2026-04-29 | Proxy | Definitive proxy statement |
| 2026-04-20 | Press release | Download , AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call, Ap |
| 2026-04-01 | Press release | AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026 |
| 2026-04-01 | Press release | AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026 |
| 2026-02-24 | Press release | Download , AbCellera Reports Full Year 2025 Business Results |
| 2026-02-24 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-24 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-11 | Press release | Download , AbCellera to Present at Upcoming Investor Conferences in March and April 2026, (opens in n |
| 2026-01-22 | Press release | Download , AbCellera to Report Full Year 2025 Financial Results on February 24, 2026, (opens in new wi |